Zacks Investment Research downgraded shares of Trupanion (NASDAQ:TRUP) from a hold rating to a sell rating in a research note released on Saturday, Zacks.com reports.

According to Zacks, “Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider of a medical insurance plan for cats and dogs. It operates primarily in Canada, Puerto Rico, and the United States. The Company serves pet owners and veterinarians. Trupanion, Inc. is headquartered in Seattle, Washington. “

Several other research firms have also commented on TRUP. BidaskClub lowered shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, June 26th. Northland Securities set a $5.00 price target on shares of Communications Systems and gave the company a buy rating in a research report on Tuesday, May 14th. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a research report on Thursday, March 21st. Finally, Guggenheim restated a buy rating and set a $95.00 price target (up previously from $90.00) on shares of VF in a research report on Thursday, May 23rd. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $43.90.

TRUP stock opened at $33.16 on Friday. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -1,105.33 and a beta of 1.32. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.14. The firm’s fifty day moving average price is $33.70. Trupanion has a one year low of $22.38 and a one year high of $46.70.

Trupanion (NASDAQ:TRUP) last released its quarterly earnings results on Thursday, May 2nd. The financial services provider reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.03). The firm had revenue of $86.98 million for the quarter, compared to analyst estimates of $85.87 million. Trupanion had a negative net margin of 0.23% and a negative return on equity of 0.59%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.05) EPS. Research analysts predict that Trupanion will post -0.07 EPS for the current year.

In other news, CRO Margaret Tooth sold 1,000 shares of Trupanion stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $33.52, for a total value of $33,520.00. Following the sale, the executive now owns 4,693 shares in the company, valued at $157,309.36. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dan Levitan sold 15,000 shares of Trupanion stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $29.56, for a total transaction of $443,400.00. Following the completion of the sale, the director now owns 73,487 shares in the company, valued at approximately $2,172,275.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,753 shares of company stock worth $1,898,572. Company insiders own 13.61% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. DAVENPORT & Co LLC grew its position in shares of Trupanion by 14.4% in the second quarter. DAVENPORT & Co LLC now owns 258,771 shares of the financial services provider’s stock valued at $9,349,000 after purchasing an additional 32,550 shares during the period. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Trupanion in the first quarter worth about $5,702,000. Clearbridge Investments LLC lifted its stake in shares of Trupanion by 38.6% in the first quarter. Clearbridge Investments LLC now owns 1,220,505 shares of the financial services provider’s stock worth $39,959,000 after buying an additional 339,812 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Trupanion in the first quarter worth about $406,000. Finally, Altrinsic Global Advisors LLC lifted its stake in shares of Trupanion by 14.1% in the first quarter. Altrinsic Global Advisors LLC now owns 161,450 shares of the financial services provider’s stock worth $5,286,000 after buying an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 97.77% of the company’s stock.

About Trupanion

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.

Featured Story: What is the Rule of 72?

Get a free copy of the Zacks research report on Trupanion (TRUP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trupanion (NASDAQ:TRUP)

Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.